Gingipain Inhibitors: The Alzheimer's Drug That Failed and Was Reborn

When a pharmaceutical company spends millions developing a drug that targets bacteria from your mouth inside the brain, it tells you something about where the science has landed. When that drug fails — and another company buys the wreckage and starts over — it tells you something even more interesting. We’ve covered the gingipain inhibitor approach to Alzheimer’s and how oral bacteria reach your brain through two distinct pathways. But the business story behind this drug — the trial results, the FDA hold, the company pivot, and the new trial now underway — reveals what happens when an idea is too promising to abandon but too complicated to get right on the first try.

The science that started it all

In 2019, Stephen Dominy and his team published a study in Science Advances that shifted the oral-brain conversation from interesting correlation to potential causation (Dominy et al., 2019). They examined postmortem brain tissue from Alzheimer’s patients and found Porphyromonas gingivalis — the keystone pathogen behind chronic periodontal disease — in the majority of samples. They also found its toxic proteases, called gingipains, and here’s the part that changed everything: the levels of those gingipains correlated directly with tau pathology and amyloid accumulation. More gingipains meant worse Alzheimer’s markers.

This wasn’t a vague statistical association. The bacteria were in the brain. Their toxic enzymes were in the brain. And the amount of enzyme tracked with disease severity.

The team then infected mice with P. gingivalis through the mouth — mimicking human gum disease — and watched what happened. The oral infection led to brain colonization, increased amyloid-beta production, neuroinflammation, and hippocampal neuron damage. Then came the part that got pharmaceutical attention: treating the infected mice with small-molecule inhibitors designed to block gingipain activity reduced bacterial load in the brain, decreased amyloid production, and rescued hippocampal neurons. Block the toxin, protect the brain.

Cortexyme bets big

Based on this preclinical evidence, a company called Cortexyme was founded with a singular focus: develop a gingipain inhibitor drug for Alzheimer’s disease. Their lead compound, atuzaginstat (COR388), was designed to cross the blood-brain barrier and block the toxic proteases that P. gingivalis produces once it reaches brain tissue.

The drug entered Phase II/III clinical trials — the GAIN trial — for mild to moderate Alzheimer’s disease. This was a significant investment, representing hundreds of millions in development costs. When a pharmaceutical company bets that much on a mechanism, it means the preclinical evidence cleared a very high bar.

A 2020 study published in Pharmacology Research & Perspectives tested the compound in aged dogs naturally infected with P. gulae, the canine equivalent of P. gingivalis. The treatment reduced bacterial infection, decreased neuroinflammation markers, and improved cognitive function. The animal data kept building.

What actually happened in the trial

The GAIN trial results, announced in October 2021, told a complicated story. The drug did not meet its co-primary endpoints in the overall population of patients with mild to moderate Alzheimer’s. On the surface, that looks like failure.

But buried in the data was something remarkable. A pre-specified subgroup analysis — not a post-hoc fishing expedition, but something the researchers planned before unblinding — found that participants with detectable P. gingivalis DNA in their saliva who received the higher dose of atuzaginstat experienced a statistically significant 57% slowing of cognitive decline as measured by ADAS-Cog11.

That’s a striking number. A 57% slowing in a neurodegenerative disease is meaningful. The problem was that the drug didn’t work in Alzheimer’s patients who didn’t have detectable P. gingivalis. The overall trial population included everyone — oral-bacteria-positive and oral-bacteria-negative — and the negative patients diluted the effect.

Then came the liver issue. The FDA placed a partial clinical hold on atuzaginstat in February 2021 due to liver abnormalities in some participants. By January 2022, that escalated to a full clinical hold. In August 2022, Cortexyme announced it was discontinuing its gingipain inhibitor program and offering the portfolio for external licensing.

The resurrection

The story didn’t end there. Cortexyme changed its name to Quince Therapeutics and shifted its focus to bone disease. In January 2023, Quince sold the former Cortexyme small-molecule protease inhibitor portfolio — including the rights to the gingipain inhibition approach — to Lighthouse Pharmaceuticals.

Lighthouse didn’t buy a failure. They bought a 57% subgroup finding and a mechanism that made biological sense. Their approach is different from Cortexyme’s in one critical way: patient selection. Instead of enrolling all Alzheimer’s patients and hoping the drug works in enough of them, Lighthouse is running the SPRING trial (Stopping PRogression of P. gINGivalis-Positive AD with Gingipain Inhibition) with a second-generation compound called LHP588. The trial aims to enroll 300 patients with mild-to-moderate Alzheimer’s disease who test positive for P. gingivalis in saliva — the exact subgroup where Cortexyme’s original drug showed the strongest effect (Lighthouse Pharmaceuticals, CTAD 2025).

This is precision medicine applied to a pathogen hypothesis. Don’t treat everyone with Alzheimer’s. Treat the people whose Alzheimer’s has a specific infectious driver. If it works, it changes the diagnostic conversation entirely — suddenly your dentist’s periodontal chart becomes relevant to your neurologist’s assessment.

Why this matters beyond the drug

Whether LHP588 succeeds or fails in clinical trials, the implications of this story extend far beyond one compound.

The subgroup finding validates the mechanism. If P. gingivalis in the brain were irrelevant to Alzheimer’s progression, you wouldn’t see a 57% slowing of cognitive decline in people who carry the bacterium. The fact that the drug only worked in P. gingivalis-positive patients is itself evidence that the bacteria are contributing to the disease in those individuals.

The two-pathway model explains the inconsistency. Not everyone with gum disease develops Alzheimer’s, and not everyone with Alzheimer’s has detectable P. gingivalis. But research shows the bacteria can reach the brain through at least two routes. The first is direct bloodstream invasion — when chronically inflamed gum tissue becomes permeable, P. gingivalis outer membrane vesicles cross the blood-brain barrier and trigger neuroinflammation (Li et al., 2023). The second route runs through the gut: swallowing oral bacteria disrupts your intestinal microbiome, alters kynurenine metabolism, and produces neurotoxic metabolites that contribute to neurodegeneration (Lee et al., 2025). Different patients may have different dominant pathways.

The business continuity signals confidence. Pharmaceutical companies don’t buy failed drug programs out of nostalgia. Lighthouse evaluated the same data everyone else saw — the liver toxicity, the missed primary endpoints, the FDA hold — and decided the 57% subgroup finding plus a refined patient selection strategy justified a second attempt. That’s a calculated bet on the underlying biology.

What you can do about your gums right now

You don’t need to wait for the SPRING trial results to act on this research. The preclinical and clinical evidence already supports taking periodontal health seriously as a brain health intervention.

1. Get a periodontal evaluation. Not just a routine cleaning — ask specifically about pocket depth measurements and signs of bone loss. A standard dental cleaning doesn’t assess these. If you’re over 40, request periodontal charting.

2. Treat bleeding gums as an active inflammatory process. Bleeding when you brush or floss isn’t normal. That inflammation is the entry point for bacteria to reach your bloodstream. See a periodontist if your dentist flags concerns.

3. Understand what’s at stake. Periodontal disease affects roughly half of adults over 35. By your 60s and 70s, that climbs to 70–80% with significant disease. And it’s largely painless in early stages. The damage accumulates silently for years — possibly decades — before anyone connects it to cognitive changes.

4. Reduce your total inflammatory burden. Everything that reduces systemic inflammation also reduces your susceptibility to periodontal disease and its downstream effects. A diet rich in diverse plant fibers, fermented foods, and anti-inflammatory fats supports a healthier bacterial environment throughout your digestive tract — including your mouth.

5. Support your oral microbiome. Oral probiotics — distinct from gut probiotics — are an emerging area. Targeted strains that colonize the mouth may help rebalance the oral microbiome. BioGaia Prodentis Oral Probiotics contain Lactobacillus reuteri DSM 17938 and L. reuteri ATCC PTA 5289, two strains studied for their ability to support gum health and reduce oral pathogens. This isn’t a substitute for periodontal treatment if you have active disease, but it’s a practical adjunct.

6. Support your gut barrier. The oral-gut-brain axis means oral health and gut health are bidirectional. A quality synbiotic supports the intestinal barrier that oral pathogens exploit. Seed DS-01 Daily Synbiotic delivers 24 clinically studied strains with a prebiotic outer capsule designed to survive stomach acid.

7. Floss like it matters — because it does. The goal isn’t removing food particles. It’s disrupting the bacterial biofilm below the gumline where P. gingivalis thrives. Wrap the floss in a C-shape around each tooth and slide it gently beneath the gumline.

What we still don’t know

The SPRING trial is still underway, and we don’t yet have results showing that blocking gingipains in humans who carry P. gingivalis actually slows Alzheimer’s progression. The subgroup finding from the GAIN trial is compelling, but it came from a trial that wasn’t designed to test that specific hypothesis as its primary endpoint. The SPRING trial is. If LHP588 succeeds, it would fundamentally reshape how we think about Alzheimer’s as a disease with an infectious component — and it would make periodontal screening a standard part of neurological assessment. If it doesn’t, the underlying science about oral bacteria in the brain still stands. It just means blocking one enzyme may not be enough.

Save for later — send this to someone who dismisses gum disease as a cosmetic issue.

Disclosure: This post contains affiliate links. If you purchase through these links, I may earn a small commission at no extra cost to you.